(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.23%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.42%) $924.40
(0.38%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases...
Stats | |
---|---|
今日成交量 | 7.88M |
平均成交量 | 1.27M |
市值 | 0.00 |
EPS | $-1.160 ( 2021-11-04 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $2.64 (1.48%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-11-19 | Zakrzewski Joseph S | Sell | 34 499 | Common Stock |
2021-11-19 | Zakrzewski Joseph S | Sell | 10 000 | Option to Purchase Common Stock |
2021-11-19 | Zakrzewski Joseph S | Sell | 7 500 | Option to Purchase Common Stock |
2021-11-19 | Zakrzewski Joseph S | Sell | 7 500 | Option to Purchase Common Stock |
2021-11-19 | Zakrzewski Joseph S | Sell | 10 000 | Option to Purchase Common Stock |
INSIDER POWER |
---|
0.00 |
Last 100 transactions |
Buy: 155 406 | Sell: 743 673 |
音量 相关性
Acceleron Pharma Inc 相关性 - 货币/商品
Acceleron Pharma Inc 财务报表
Annual | 2020 |
营收: | $92.52M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.92 |
FY | 2020 |
营收: | $92.52M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.92 |
FY | 2019 |
营收: | $73.99M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.38 |
FY | 2018 |
营收: | $13.99M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.59 |
Financial Reports:
No articles found.
Acceleron Pharma Inc
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。